Imitation of β-lactam binding enables broad-spectrum metallo-β-lactamase inhibitors
Jürgen Brem,Tharindi Panduwawala,Jon Ulf Hansen,Joanne Hewitt,Edgars Liepins,Pawel Donets,Laura Espina,Alistair J M Farley,Kirill Shubin,Gonzalo Gomez Campillos,Paula Kiuru,Shifali Shishodia,Daniel Krahn,Robert K Leśniak,Juliane Schmidt Adrian,Karina Calvopiña,María-Carmen Turrientes,Madeline E Kavanagh,Dmitrijs Lubriks,Philip Hinchliffe,Gareth W Langley,Ali F Aboklaish,Anders Eneroth,Maria Backlund,Andrei G Baran,Elisabet I Nielsen,Michael Speake,Janis Kuka,John Robinson,Solveiga Grinberga,Lindsay Robinson,Michael A McDonough,Anna M Rydzik,Thomas M Leissing,Juan Carlos Jimenez-Castellanos,Matthew B Avison,Solange Da Silva Pinto,Andrew D Pannifer,Marina Martjuga,Emma Widlake,Martins Priede,Iva Hopkins Navratilova,Marek Gniadkowski,Anna Karin Belfrage,Peter Brandt,Jari Yli-Kauhaluoma,Eric Bacque,Malcolm G P Page,Fredrik Björkling,Jonathan M Tyrrell,James Spencer,Pauline A Lang,Pawel Baranczewski,Rafael Cantón,Stuart P McElroy,Philip S Jones,Fernando Baquero,Edgars Suna,Angus Morrison,Timothy R Walsh,Christopher J Schofield
DOI: https://doi.org/10.1038/s41557-021-00831-x
Abstract:Carbapenems are vital antibiotics, but their efficacy is increasingly compromised by metallo-β-lactamases (MBLs). Here we report the discovery and optimization of potent broad-spectrum MBL inhibitors. A high-throughput screen for NDM-1 inhibitors identified indole-2-carboxylates (InCs) as potential β-lactamase stable β-lactam mimics. Subsequent structure-activity relationship studies revealed InCs as a new class of potent MBL inhibitor, active against all MBL classes of major clinical relevance. Crystallographic studies revealed a binding mode of the InCs to MBLs that, in some regards, mimics that predicted for intact carbapenems, including with respect to maintenance of the Zn(II)-bound hydroxyl, and in other regards mimics binding observed in MBL-carbapenem product complexes. InCs restore carbapenem activity against multiple drug-resistant Gram-negative bacteria and have a low frequency of resistance. InCs also have a good in vivo safety profile, and when combined with meropenem show a strong in vivo efficacy in peritonitis and thigh mouse infection models.